Loading...
Loading...
Sucampo Pharmaceuticals
SCMP today announced that it has received approval of an sNDA for
RESCULA® (unoprostone isopropyl ophthalmic solution) 0.15%
for the lowering of intraocular pressure (IOP) in patients with
open-angle glaucoma or ocular hypertension from the U.S. Food and Drug
Administration (FDA). Open-angle glaucoma is the most common form of
glaucoma. Sucampo intends to commercialize RESCULA in the first quarter
of 2013.
According to the approved product labeling, RESCULA may be used as a
first-line agent or concomitantly with other topical ophthalmic drug
products to lower intraocular pressure. RESCULA is a BK (Big Potassium)
channel activator, which is different from other IOP lowering agents.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in